Article

Pathophysiology of multiple myeloma bone disease.

Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh, and Division of Hematology/Oncology, Veterans Administration Pittsburgh Healthcare System, Research and Development, PA 15232, USA.
Hematology/Oncology Clinics of North America (Impact Factor: 2.08). 01/2008; 21(6):1035-49, viii. DOI: 10.1016/j.hoc.2007.08.009
Source: PubMed

ABSTRACT Multiple myeloma is a plasma cell malignancy characterized by the frequent development of osteolytic bone lesions. The multiple myeloma-induced bone destruction is a result of the increased activity of osteoclasts that occurs adjacent to multiple myeloma cells. This activity is accompanied by suppressed osteoblast differentiation and activity, resulting in severely impaired bone formation and development of devastating osteolytic lesions. Recently the biologic mechanism involved in the imbalance between osteoclast activation and osteoblast inhibition induced by multiple myeloma cells has begun to be clarified. In this article, the pathophysiology underlying the imbalanced bone remodeling and potential new strategies for the treatment of bone disease in multiple myeloma are reviewed.

0 Bookmarks
 · 
92 Views
  • Seminars in Hematology - SEMIN HEMATOL. 01/2011; 23(5):228-229.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Recent biological advances have provided the framework for novel therapeutic strategies in oncology. Many new treatments are now based on standard cytotoxic drugs plus biologic agents. In Multiple Myeloma, a plasma cell neoplasm characterized by a severe bone disease, biologic drugs such as proteasome inhibitors and immunomodulatory agents, above their antineoplastic efficacy have a beneficial effects on bone disease. Bortezomib, a clinically available proteasome inhibitor active against myeloma, induces the differentiation of mesenchymal stem/progenitor cells into osteoblasts, resulting in new bone formation. Immunomodulatory drugs (e.g., thalidomide and lenalidomide), which are active against myeloma, also block the activity of bone-resorbing osteoclasts. These data reflect the utility of targeting endogenous mesenchymal stem/progenitor cells for the purpose of tissue repair and suggest that combining different classes of agents that are antineoplastic and also inhibit bone destruction and increase bone formation should be very beneficial for myeloma patients suffering from severe bone disease.
    Clinical Cases in Mineral and Bone Metabolism 01/2013; 10(3):183-186.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Interactions of myeloma cells with the bone marrow microenvironment lead to enhanced osteoclast recruitment and impaired osteoblast activity. Recent evidence revealed that the proteasome inhibitor bortezomib stimulates osteoblast differentiation, but the mechanisms are not fully elucidated. We hypothesized that bortezomib could influence osteoblastic differentiation via alteration of vitamin D signalling by blocking the proteasomal degradation of the vitamin D receptor (VDR). This is of clinical importance, since a high rate of vitamin D deficiency was reported in myeloma patients. We performed cocultures of primary human mesenchymal stem cells (hMSC) and human osteoblasts (hOB) with myeloma cells, which resulted in an inhibition of the vitamin D dependent differentiation of osteoblast precursors. Treatment with bortezomib led to a moderate increase of osteoblastic differentiation markers in hMSC and hOB. Importantly, this effect could be strikingly increased when vitamin D was added. Bortezomib led to enhanced nuclear VDR protein levels in hMSC. Primary hMSC transfected with a VDR luciferase reporter construct showed a strong increase in VDR signalling with bortezomib. In summary, stimulation of VDR signalling is a mechanism for the bortezomib-induced stimulation of osteoblastic differentiation. The data suggest that supplementation of vitamin D in myeloma patients treated with bortezomib is crucial for optimal bone formation. © 2013 John Wiley & Sons A/S.
    European Journal Of Haematology 01/2013; · 2.55 Impact Factor